Mark J. Pettenati - Concepedia

Author

Mark J. Pettenati

Also Known As

M J Pettenati, M Pettenati, M. J. PETTENATI, M. J. Pettenati, M. Pettenati, M.J. Pettenati, MARK J. PETTENATI, Mark J Pettenati, Mark J. Pettenati, Mark Pettenati

190

Publications

8.1K

Citations

H-Index

121

Concepts

All Affiliations

Wake Forest University Atrium Health Wake Forest Baptist University of Alabama at Birmingham University Medical Center The Ohio State University

About

Mark J. Pettenati is an author at Wake Forest University specializing in medicine, genetics, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	41	3.2K
2	Health Sciences	5	5	799
3	Natural Sciences	5	5	345
4	Public Health	3	3	109
5	Biochemistry	3	3	265

Mark J. Pettenati

Publications

Citations

H-Index

Page 1

	Year	Citations
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Clara D. Bloomfield, David Lawrence, John C. Byrd, PubMed Mixed-phenotype Acute LeukemiaPathologyPharmacotherapyHigh-dose Cytarabine IntensificationMyeloid Neoplasia	1998	696
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia Krzysztof Mrózek, Guido Marcucci, Deedra Nicolet, Journal of Clinical Oncology	2012	405
The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies Jan O. Korbel, Tal Tirosh‐Wagner, Alexander E. Urban, Proceedings of the National Academy of Sciences Down SyndromeSevere Mental RetardationDevelopmental BiologyMendelian DisorderGenetic Disorder	2009	393
Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study Guido Marcucci, Krzysztof Mrózek, Amy S. Ruppert, Journal of Clinical Oncology	2005	381
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461 Sherif S. Farag, Kellie J. Archer, Krzysztof Mrózek, Blood	2006	329
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Meir Wetzler, Richard K. Dodge, Krzysztof Mrózek, PubMed	1999	313
Wiedemann-Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature Mark J. Pettenati, Jonathan L. Haines, Rodney R. Higgins, Human Genetics Mendelian DisorderGenetic DisorderPathologyNew CasesCytogenetic Data	1986	299
Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461 John C. Byrd, Amy S. Ruppert, Krzysztof Mrózek, Journal of Clinical Oncology	2004	218
Down syndrome congenital heart disease: A narrowed region and a candidate gene Gillian M. Barlow, Xiao–Ning Chen, Gary E. Lyons, Genetics in Medicine Down SyndromeHeart FailurePediatric Heart DiseaseGeneticsNarrowed Region	2001	194
Transferable anticancer innate immunity in spontaneous regression/complete resistance mice Amy M. Hicks, Gregory Riedlinger, Mark C. Willingham, Proceedings of the National Academy of Sciences InflammationRapid InfiltrationCancer ImmunosurveillanceInnate Immune SystemImmunology	2006	164

Page 1